In a report issued on April 27, Daina Graybosch from Leerink Partners maintained a Buy rating on LAVA Therapeutics (LVTX – Research Report), with a price target of $23.00. The company's shares closed last Monday at $4.24, close to its 52-week low of $3.85. According to TipRanks.com, Graybosch has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -24.3% and a 24.2% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Silverback Therapeutics, Werewolf Therapeutics, and Century Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for LAVA Therapeutics with a $21.
https://www.tipranks.com/news/blurbs/leerink-partners-thinks-lava-therapeutics-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more LAVA Therapeutics NV Charts.
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more LAVA Therapeutics NV Charts.